6533b829fe1ef96bd128a475

RESEARCH PRODUCT

ANCA-associated vasculitides: Recommendations of the French Vasculitis Study Group on the use of immunosuppressants and biotherapies for remission induction and maintenance

Maxime SamsonYoann CrabolBernard BonnotteOlivier AumaîtreNoémie Jourde-chicheBenjamin TerrierBenjamin TerrierMikael EbboCécile-audrey DurelLoïc GuillevinAlexandre BelotXavier PuéchalJean-christophe LegaFrederic VandergheynstPierre CharlesThomas QuemeneurGrégory PugnetCamillo Ribi

subject

medicine.medical_specialtyCardiologyAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisMaintenance Chemotherapy03 medical and health sciencesRemission induction0302 clinical medicineMaintenance therapymedicineHumans030212 general & internal medicineMedical prescriptionIntensive care medicineSocieties Medical030203 arthritis & rheumatologybusiness.industryRemission InductionGranulomatosis with PolyangiitisGeneral Medicinemedicine.diseaseBiological TherapyPractice Guidelines as TopicRituximabFranceGranulomatosis with polyangiitisbusinessMicroscopic polyangiitisVasculitisMepolizumabImmunosuppressive Agentsmedicine.drug

description

Treatment of vasculitides associated with anti-neutrophil cytoplasm antibodies (ANCA) (AAVs) has evolved dramatically in recent years, particularly since the demonstration of rituximab efficacy as remission induction and maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. In 2013, the French Vasculitis Study Group (FVSG) published recommendations for its use by clinicians. Since then, new data have made it possible to better specify and codify prescription of rituximab to treat AAVs. Herein, the FVSG Recommendations Committee, an expert panel comprised of physicians with extensive experience in the treatment and management of vasculitides, presents its consensus guidelines based on literature analysis, the results of prospective therapeutic trials and personal experience.

yearjournalcountryeditionlanguage
2019-09-28La Presse Médicale
https://doi.org/10.1016/j.lpm.2020.104031